Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Oral E7080 (lenvatinib) plus Best Supportive Care versus Best Supportive Care Alone in Non-squamous NSCLC After ≥2 Prior Regimens
2011-002347-10Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing lenvatinib + best supportive care with placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Aug 2011; status: completed.
02
Drugs
lenvatinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2011-002347-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002347-10.